Skip to content

JASP-1 for Children Recently Diagnosed and Their Parents

Benefits of a Juvenile Arthritis Support Program (JASP-1) for Children Recently Diagnosed With Juvenile Idiopathic Arthritis (JIA) and Their Parents

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06284616
Acronym
JASP-1
Enrollment
82
Registered
2024-02-29
Start date
2019-08-15
Completion date
2023-12-31
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

JIA, Patient Outcome Assessment, Patient Satisfaction, Support Program

Keywords

JIA, Support program, Patient Satisfaction, Patient outcome assessment

Brief summary

To implement and evaluate a patient-and family-centered Juvenile Arthritis Support Program during one year (JASP-1) for children recently diagnosed with JIA and their parents and after 12 months compare satistaction with care and health outcomes with a control group receiving standard care.

Detailed description

Children diagnosed with JIA (n=50) and their parents were offered the opportunity to participate in the JASP-1 from the time of diagnosis and the following year. One year after the JIA diagnosis, the children and/or their parents were invited to answer a study-specific questionnaire comprising 16 questions. The questionnaire assessed their experiences with the information, communication, participation, and emotional support they had received during the first year with JIA. In order to compare outcomes, the questionnaire was answered by both participants in JASP-1 and patients and parents receiving standard care (n=25). One example of a question is; If you asked questions to the health care professionals, did you get answers that you understood? Response alternatives range from No, not at all to Yes, Completely ona 5-point Likert scale. In Swedish Pediatric Rheumatology Quality Register (PedSRQ) information about treatment, disease- and joint activity (registered by Medical doctor), and Patient Reported Outcome Measures (PROM), are measured. The total Child Health Activity Questionnaire (CHAQ-score), as well as active joints and treatment at 12 months was registered in the PedSRQ and analyzed. The study specific questionnaire measuring patient satisfaction has been developed in collaboration with the Swedish Municipalities and County councils. Experimental and descriptive analyses will be performed using software for statistical analysis, SPSS. Distributions of responses will be calculated in percentage. Differences in proportions between groups will be determined by performing chi-square tests.

Interventions

BEHAVIORALJASP-1

patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic

Sponsors

Region Stockholm
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

All patient receiving a JIA diagnose was offered to participate in JASP-1. The controls had received diagnose before the start of the study.

Intervention model description

The study is a non-randomized intervention study with 2 groups receiving either a Support program (JASP-1) or standard care

Eligibility

Sex/Gender
ALL
Age
1 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Children 1-16 years old * Diagnosed with JIA at their first visit to the PRC

Exclusion criteria

* Children that did not fulfil the criteria for JIA * Children/parents who could not understand the Swedish language.

Design outcomes

Primary

MeasureTime frameDescription
Rate of Patient Reported Experienced Measures (PREM)12 monthsA study specific PREM questionnaire with 16 items. 5 point likert scale

Secondary

MeasureTime frameDescription
Rate of Overall perceived health12 monthsOne item on a 5 point likert scale, range from not good at all to totally good
Rate of Child Health Activity Questionnaire (CHAQ)12 monthsCHAQ assesses functional ability and assists in understanding the impact of the disease on the child´s daily life. On a Visual Analog Scale (VAS) ranging 0 to 10
Number of active joints12 monthsMedical doctors assessment of the childs actice joints

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026